title: Vitamin D supplementation in obese type 2 diabetes subjects in Ajman, UAE: a randomized controlled double-blinded clinical trial.
abstract: OBJECTIVE
  To study the effect of Vitamin D3 supplementation on metabolic control in an obese type 2 diabetes Emirati population.
  
  
  METHODS
  This randomized double-blind clinical trial was conducted with 87 vitamin D-deficient obese, type 2 diabetic participants. The vitamin D-group (n=45) and the placebo group (n=42) were matched for gender, age, HbA1c and 25-hydroxy vitamin D (25(OH) D) at the baseline. The study was divided into two phases of 3 months each; in phase 1, the vitamin D-group received 6000 IU vitamin D3/day followed by 3000 IU vitamin D3/day in phase 2, whereas the placebo group (n=42) received matching placebo.
  
  
  RESULTS
  After supplementation, serum 25(OH) D peaked in the vitamin D-group in phase 1 (77.2±30.1 nmol/l, P=0.003) followed by a decrease in the phase 2 (61.4±18.8 nmol/l, P=0.006), although this was higher compared with baseline. In the placebo group, no difference was observed in the serum 25(OH) D levels throughout the intervention. Relative to baseline serum, parathyroid hormone decreased 24% (P=0.003) in the vitamin D-group in phase 2, but remained unchanged in the placebo group. No significant changes were observed in blood pressure, fasting blood glucose, HbA1c, C-peptide, creatinine, phosphorous, alkaline phosphatase, lipids, C-reactive protein or thyroid stimulating hormone concentrations compared with baseline in either group.
  
  
  CONCLUSIONS
  Six months of vitamin D3 supplementation to vitamin D-deficient obese type 2 diabetes patients in the UAE normalized the vitamin D status and reduced the incidence of eucalcemic parathyroid hormone elevation but showed no effect on the metabolic control.
authors.affiliation: Rashid Center for Diabetes and Research, Ajman, UAE.
authors.forename: A
authors.initials: A
authors.lastname: Sadiya
authors.affiliation: Rashid Center for Diabetes and Research, Ajman, UAE.
authors.forename: S M
authors.initials: SM
authors.lastname: Ahmed
authors.affiliation: Kalmar County Hospital, Kalmar, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Carlsson
authors.affiliation: Rashid Center for Diabetes and Research, Ajman, UAE.
authors.forename: Y
authors.initials: Y
authors.lastname: Tesfa
authors.affiliation: Rashid Center for Diabetes and Research, Ajman, UAE.
authors.forename: M
authors.initials: M
authors.lastname: George
authors.affiliation: Rashid Center for Diabetes and Research, Ajman, UAE.
authors.forename: S H
authors.initials: SH
authors.lastname: Ali
authors.affiliation: Rashid Center for Diabetes and Research, Ajman, UAE.
authors.forename: H H
authors.initials: HH
authors.lastname: Siddieg
authors.affiliation: Rashid Center for Diabetes and Research, Ajman, UAE.
authors.forename: S
authors.initials: S
authors.lastname: Abusnana
mesh_terms: D000328:Adult; D015992:Body Mass Index; D002112:Calcifediol / Q000097:blood; D002762:Cholecalciferol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D019587:Dietary Supplements / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D015994:Incidence; D059012:Lost to Follow-Up; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications*; D010281:Parathyroid Hormone / Q000097:blood; D010352:Patient Dropouts; D014479:United Arab Emirates / Q000453:epidemiology; D014808:Vitamin D Deficiency / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D002112:Calcifediol; D002762:Cholecalciferol; D006442:Glycated Hemoglobin; D010281:Parathyroid Hormone; C470125:PTH protein, human; C517652:hemoglobin A1c protein, human